Placebo to match momelotinib

DRUG3 trials

Conditions

Metastatic Pancreatic Ductal AdenocarcinomaPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisPrimary Myelofibrosis

Phase 3

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

CompletedNCT01969838

Sierra Oncology LLC - a GSK companyPost-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2013-12-06End: 2019-05-02Updated: 2023-05-12

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

TerminatedNCT02101021

Sierra Oncology LLC - a GSK companyMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2014-06-02End: 2017-04-10Updated: 2023-06-29

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

CompletedNCT04173494

Sierra Oncology LLC - a GSK companyPost-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2020-02-07End: 2022-12-29Updated: 2023-11-01

Blood2025-11-031 citations

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Blood2025-11-03

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Blood2025-11-03

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Blood2025-11-03

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Blood2025-11-03

Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysis

Blood2025-11-03

Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia

International Journal of Hematology2025-07-21

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials

eJHaem2025-06-01

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.

2024-10-167 citations

Association between hemoglobin (Hb) improvement and patient-reported outcomes (PROs) in patients (pts) with myelofibrosis (MF) and anemia: Post hoc pooled analysis of momelotinib (MMB) phase 3 trials.

Journal of Clinical Oncology2024-06-012 citations

Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.

Journal of Clinical Oncology2024-06-01

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial

Leukemia & lymphoma/Leukemia and lymphoma2024-03-1910 citations

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

eJHaem2024-02-0117 citations

JAK2 Inhibitors & Myelofibrosis

Oncology Times2023-12-05

Estimating Transfusion-Related Medical Costs and Associated Time Burden in Patients with Myelofibrosis: A Comparison of Momelotinib Vs Ruxolitinib Based on Simplify-1

Blood2023-11-023 citations

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Blood2023-11-023 citations

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Blood2023-11-023 citations

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Blood2023-11-021 citations

Utilization of healthcare services in acute myocardial infarction and the risk of out-of-hospital cardiac death

Panminerva Medica2023-08-03

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)

HemaSphere2023-08-011 citations

17 more papers not shown

Placebo to match momelotinib

Sponsors

Conditions

Phase 3

Related Papers